[1
]
From Dalhousie University, Halifax, NS (R.G.L.), Clinical Research (K.P.) and Probity
Medical Research (K.P., L.S.), Waterloo, ON, and Stratica Medical and Probity Medical
Research, Edmonton, AB (N.W.) - all in Canada; University of Alabama, Birmingham (B.E.E.);
Mount Sinai Hospital, New York (M.L.); Dermatologikum Hamburg and Georg-August-Universität,
Göttingen, Germany (K.R.); Dermatology Centre, Salford Royal Hospital, University
of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
(C.E.M.G.); Hospital de Sant Pau, Barcelona (L.P.); Jikei University School of Medicine,
Tokyo (H.N.); Veracity Clinical Research, Woolloongabba, QLD, Australia (L.S.); Faculty
of Medicine, Department of Dermatology, University of Iceland, Reykjavik (B.S.); Dermos,
Guatemala City, Guatemala (E.R.); Department of Dermatology, National Taiwan University
Hospital and National Taiwan University College of Medicine, Taipei (T.-F.T.); University
of Texas Health Science Center and Center for Clinical Studies, Houston (S.T.); and
Novartis Pharma, Basel, Switzerland (T.S., I.H., M.N., A.K., S.H., C.P.).